New Study Shows Majority Of Omnipod® Insulin Management System Users Report Significant Clinical And Quality Of Life Benefits

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced the online publication of new data in Diabetes Technology & Therapeutics 1 that continue to validate the substantial quality of life benefits of the Omnipod System. In this study, more than 1,200 current adult Omnipod users with type 1 diabetes completed an online questionnaire to examine perceived changes in quality of life and glycemic control. The majority reported positive changes in perceived control over their diabetes (72.5%), diabetes distress (69.6%), overall well-being (53.5%) and hypoglycemic safety (50.6%) since starting use of Omnipod (P<0.001).

The majority of patients also reported significant improvement in glycemic control (64.2%) since starting on the Omnipod System, with more than one-third (35.2%) describing a decrease in severe hypoglycemic episodes. Approximately 60% of patients previously used multiple daily injections and approximately 40% were previously treated with traditional tubed pumps.

"While past evidence has suggested that all insulin pumps may contribute to improved quality of life for people with type 1 diabetes, there have been few studies until now that have examined the quality of life impact of the newer, more differentiated systems like Omnipod," said William Polonsky, PhD, principal investigator of the study and associate clinical professor in psychiatry at the University of California San Diego. "These findings provide insight into the Omnipod user experience and demonstrate that users' trust in the Omnipod System and reported improvements in glycemic control are significant factors that can enhance the individual's quality of life."

"The results of this study reinforce Omnipod's differentiated design and the freedom and improved quality of life it offers," said Patrick Sullivan, Chairman and Chief Executive Officer. "The body of evidence supporting Omnipod's unique advantages continues to grow and is driving increased awareness so more people can benefit from this remarkable technology."

If you liked this article you might like

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

Analysts' Actions -- Express Scripts, Lions Gate, Qorvo, Whole Foods and More

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Insulet (PODD) Is Strong On High Volume Today

On Tap for Analysts: Boston Scientific, Ford, Western Digital